SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

29 May 2023 Evaluate
The revenue for the March 2023 quarter is pegged at Rs. 14016.30 millions, about 19.00% up against Rs. 11778.00 millions recorded during the year-ago period.The Company's Net profit for the March 2023 quarter have declined marginally to Rs. 848.20  millions as against Rs. 1101.40 millions reported during the corresponding quarter ended.The company reported a good operating profit of 2091.10 millions compared to 1944.80 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 14016.30 11778.00 19.00 58146.20 54383.00 6.92 58146.20 54383.00 6.92
Other Income 334.70 125.30 167.12 1111.90 529.20 110.11 1111.90 529.20 110.11
PBIDT 2091.10 1944.80 7.52 10230.40 12910.00 -20.76 10230.40 12910.00 -20.76
Interest 176.90 32.30 447.68 439.20 72.40 506.63 439.20 72.40 506.63
PBDT 1914.20 1912.50 0.09 9791.20 12837.60 -23.73 9791.20 12837.60 -23.73
Depreciation 592.10 538.10 10.04 2286.30 2096.50 9.05 2286.30 2096.50 9.05
PBT 1322.10 1374.40 -3.81 7504.90 10741.10 -30.13 7504.90 10741.10 -30.13
TAX 473.90 273.00 73.59 2447.90 2137.40 14.53 2447.90 2137.40 14.53
Deferred Tax 84.40 -36.80 -329.35 208.40 164.60 26.61 208.40 164.60 26.61
PAT 848.20 1101.40 -22.99 5057.00 8603.70 -41.22 5057.00 8603.70 -41.22
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 14.92 16.51 -9.65 17.59 23.74 -25.88 17.59 23.74 -25.88

Ipca Laboratories Share Price

1575.00 31.05 (2.01%)
06-May-2026 14:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1854.60
Dr. Reddys Lab 1325.40
Cipla 1369.00
Zydus Lifesciences 939.00
Lupin 2448.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×